Marlio Charles Mosseri Purchases 28,043 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri purchased 28,043 shares of the stock in a transaction dated Wednesday, June 18th. The shares were purchased at an average price of $8.05 per share, for a total transaction of $225,746.15. Following the completion of the transaction, the insider now owns 2,976,203 shares in the company, valued at $23,958,434.15. This trade represents a 0.95% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Tuesday, June 17th, Marlio Charles Mosseri purchased 5,399 shares of Nuvectis Pharma stock. The stock was acquired at an average price of $8.11 per share, for a total transaction of $43,785.89.
• On Monday, May 12th, Marlio Charles Mosseri acquired 21,167 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $8.11 per share, with a total value of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was acquired at an average price of $8.65 per share, for a total transaction of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri bought 12,444 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $8.59 per share, with a total value of $106,893.96.

Nuvectis Pharma Price Performance

Nuvectis Pharma stock traded down $0.17 during mid-day trading on Monday, hitting $7.96. The company's stock had a trading volume of 116,327 shares, compared to its average volume of 129,219. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $11.80. The company has a market cap of $166.28 million, a PE ratio of -7.04 and a beta of -0.16. The firm's 50 day moving average is $9.28 and its 200 day moving average is $7.72.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. As a group, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded Nuvectis Pharma from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price (up from $11.00) on shares of Nuvectis Pharma in a report on Wednesday, April 30th. Maxim Group initiated coverage on Nuvectis Pharma in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 price target on the stock. Finally, Laidlaw started coverage on shares of Nuvectis Pharma in a research note on Monday, March 17th. They set a "buy" rating and a $19.00 price objective for the company.

Institutional Investors Weigh In On Nuvectis Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new position in shares of Nuvectis Pharma in the fourth quarter worth $135,000. Baxter Bros Inc. grew its stake in Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock valued at $81,000 after purchasing an additional 2,500 shares in the last quarter. Marshall Wace LLP increased its position in Nuvectis Pharma by 191.0% in the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after purchasing an additional 81,757 shares during the last quarter. Northern Trust Corp raised its stake in shares of Nuvectis Pharma by 68.7% during the 4th quarter. Northern Trust Corp now owns 25,725 shares of the company's stock worth $139,000 after purchasing an additional 10,472 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Nuvectis Pharma during the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.